FXYD3 (FXYD-3; Mat-8; PLML) with two splice variants, one of 87 aas with 2 TMSs (an N-terminal leader sequence and a central very hydrophobic TMS) and the other of 116 aas and 2 TMSs (Bibert et al. 2006). Both FXYD3 variants co-immunoprecipitate with the Na,K-ATPase. They both associate stably with Na,K-ATPase isozymes but not with the H,K-ATPase or Ca-ATPase. The short human FXYD3 has 72% sequence identity with mouse FXYD3, whereas long human FXYD3 is identical to the short human FXYD3 but has a 26-amino acid insertion after the transmembrane domain. Short and long human FXYD3 RNAs and proteins are differentially expressed during differentiation with long FXYD3 being mainly expressed in nondifferentiated cells while short FXYD3 is expressed in differentiated cells (Bibert et al. 2006). Overexpression of FXYD3, as it occurs in pancreatic cancer, may contribute to the proliferative activity of this malignancy (Kayed et al. 2006).
|Protein Name:||FXYD domain-containing ion transport regulator 3|
|Species:||Homo sapiens (Human)  |
|Number of TMSs:||1|
1: MQKVTLGLLV FLAGFPVLDA NDLEDKNSPF YYGAPYIFVK RMGGQMERTQ AGTEVPSTFL
61: LDWHSLQVGG LICAGVLCAM GIIIVMSAKC KCKFGQKSGH HPGETPPLIT PGSAQS